ASH: Reduced-Dose Anticoagulants Not Noninferior for Recurrent VTE

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 6, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 6, 2024 -- Noninferiority of reduced- versus full-dose anticoagulants cannot be proven in patients with venous thromboembolism who need extended anticoagulation, according to a study to be presented at the annual meeting of the American Society of Hematology, held from Dec. 7 to 10 in San Diego.

Francis Couturaud, M.D., Ph.D., from the University of Brest in France, and colleagues conducted a multicenter, prospective, randomized trial comparing extended anticoagulation with reduced-dose versus full-dose direct oral anticoagulants in patients with venous thromboembolism at high risk for recurrence, who were initially treated for six to 24 months.

The researchers found that recurrent venous thromboembolism occurred in 19 of 1,383 patients in the reduced-dose group versus 15 of 1,385 in the full-dose group during the 36-month median follow-up (five-year cumulative incidence, 2.2 versus 1.8 percent; hazard ratio, 1.32; 95 percent confidence interval, 0.67 to 2.60; P = 0.23 for noninferiority). Clinically relevant bleeding occurred in 96 patients in the reduced-dose group and 154 in the full-dose group (five-year cumulative incidence, 9.9 versus 15.2 percent). The composite outcome of recurrent venous thromboembolism and clinically relevant bleeding occurred in 113 and 166 patients in the reduced- and full-dose groups, respectively (five-year cumulative incidence, 11.8 versus 16.5 percent). All-cause death occurred in 4.3 and 6.1 percent of patients in the reduced- and full-dose groups, respectively.

"The noninferiority of a reduced-dose versus a full-dose of direct anticoagulants to prevent recurrent venous thromboembolism could not be proven," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Abstract

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-12-07 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords